Catherine Moukheibir has been in C-level positions in several European biotech companies after an initial career in strategy consulting and investment banking in Boston and London. Her particular experience lies in aligning corporate and financial strategies appropriate to various stages of a biotech’s development, on the continuum from venture capital funding to public market or M&A. She is currently non-executive Chairman of MedDay Pharma S.A., non-executive Board member of Creabilis, non-executive Board member at Zealand Pharma and Chair of the Audit Committee, non-executive Board member and member of the Audit Committee at Cerenis and Ablynx and Advisory Board member at the Imperial College Business School. She is also a member of the three-person management Board at Innate Pharma where she is responsible for financial and corporate strategy. Catherine Moukheibir holds an MBA from Yale University.